ametiniib + bevacizumab

Ametiniib + bevacizumab is an investigational combination therapy consisting of ametiniib (a small molecule tyrosine kinase inhibitor) and bevacizumab (a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A). Bevacizumab inhibits angiogenesis by binding to VEGF-A and preventing it from activating its receptors on endothelial cells. This starves tumors of their blood supply and nutrients needed for growth[1][5]. The mechanism of action for ametiniib is not established in the provided sources; however, as a "-tinib" compound it likely targets one or more receptor tyrosine kinases involved in cancer cell proliferation or survival. The combination aims to provide synergistic antitumor effects by simultaneously inhibiting tumor angiogenesis and oncogenic signaling pathways.

Brand names

AvastinAbevmyAlymsysAvziviAybintioJobevneLytenavaMvasiOyavasVegzelmaZirabev